Rain Therapeutics Inc.
NASDAQ:RAIN
1.21 (USD) • At close January 25, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Rain Therapeutics Inc. |
Symbool | RAIN |
Munteenheid | USD |
Prijs | 1.21 |
Beurswaarde | 44,014,599 |
Dividendpercentage | 0% |
52-weken bereik | 0.82 - 11.32 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Avanish Vellanki M.B.A. |
Website | https://www.rainthera.com |
An error occurred while fetching data.
Over Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)